Showing 1 to 6 of 6 Clinical Trials
CLINICAL TRIAL
    Trial No
    ClinicalTrials.gov ID
Principal Investigator
Coordinator
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
    MK-5909-005 (REJOICE-GI01)
    NCT06864169
     Recruiting
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Colon and Rectum
Hepatic Ducts
Oesophagus
Pancreas
Stomach
Dr. Francine Aubin

Adeline Hamon
  514-890-8000 poste 30737
A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer
    ARTEMIDE-Gastric01
    NCT06764875
     Recruiting
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN  

Stomach Dr. Sara Soldera

A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer
    ARTEMIDE-Gastric01
    NCT06764875
     Recruiting
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS  

Stomach Dr. Maxime Chénard-Poirier

Maryse Gingras
  418-691-5781
A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
    CCTG GA4
    NCT06043427
     Recruiting
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL  

Oesophagus
Stomach
Dr. Setareh Samimi

Marie-Anne Capobianco
  514-338-2222 poste 3493
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
    TroFuse-015
    NCT06356311
     Recruiting
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN  

Oesophagus
Stomach
Dr. Sara Soldera

A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
    CCTG GA4
    NCT06043427
     Recruiting
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Oesophagus
Stomach
Dr. Mustapha Tehfé

Chantal Gosselin
  514-890-8000 poste 24892